Policy & Regulation
Verastem Oncology presents two-year follow-up data on avutometinib and defactinib in recurrent low-grade serous ovarian cancer
10 April 2026 - Biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) on Friday announced two-year median follow-up results from the Phase 2 RAMP 201 clinical trial of Avmapki Fakzynja combination...
DualityBio reports China NMPA acceptance of BLA for T-Pam for treatment of unresectable or metastatic HER2-positive breast cancer
10 April 2026 - Chinese biopharmaceutical company DualityBio (HK:9606) announced on Thursday that the Biologics License Application (BLA) for the investigational antibody-drug conjugate (ADC) trastuzu...
Gan & Lee and JW Pharmaceutical sign licensing deal for Bofanglutide Injection in South Korea
10 April 2026 - Chinese pharmaceutical company Gan & Lee Pharmaceuticals (SSE:603087) announced on Thursday that it has entered into an exclusive licensing agreement with JW Pharmaceutical, a phar...
Oricell Therapeutics completes USD110m pre-IPO financing
10 April 2026 - Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company developing next-generation cell therapies for oncology and immunology, announced on Thursday the cumulativ...
ArkBio completes first cohort dosing in Australian phase I trial of antiviral drug-Fc conjugate for influenza
10 April 2026 - Chinese biopharmaceutical company Shanghai Ark Biopharmaceutical Co Ltd. (ArkBio) announced on Thursday that the first cohort of healthy volunteers has been dosed in a phase I clinical...
Tempus expands oncology collaboration with Gilead to accelerate AI-driven R&D
9 April 2026 - Technology company Tempus AI Inc (NASDAQ:TEM) on Thursday announced an expanded multi-year collaboration with biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) to support the ...